Jenex (TSXV: JEN) Announces Continuation to BC and Name Change to "Therma Bright Inc."
Toronto, Ontario - February 7, 2018 (Newsfile Corp.) (Investorideas.com Newswire) The Jenex Corporation (TSXV: JEN), ("Jenex" or the "Company"), a progressive medical device technology company, announces that it will be continued from the laws of Alberta to the laws of British Columbia under the Business Corporation Act (BC) effective February 8, 2018 (the "Continuation"). The Continuation was approved by the shareholders of the Company at the annual general and special meeting of shareholders held on November 15, 2017 (the "Meeting"). The principal effects of the Continuation are set out in detail in the information circular for the Meeting. Charter documents for the Continuation will be filed on SEDAR at www.sedar.com on February 8, 2018.
The Company is also pleased to announce that it will be changing its name to "Therma Bright Inc." effective February 8, 2018.
The common shares of the Company will commence trading under the new name on the TSX Venture Exchange with the new trading symbol "THRM" at the opening of trading on February 8, 2018.
There is no change in the share capital of the Company, and shareholders are not required to exchange their existing share certificates for new certificates. The Company's new CUSIP number is 883426108 and its new ISIN number is CA8834261080.
Jenex is a progressive medical device technology company focused on providing consumers with quality medical devices that address their dermatological needs. Clear and healthy skin for all is at the core of Jenex's philosophy as is the belief that such outcomes should not be a privilege for only those who can afford costly procedures and treatments. The Company's breakthrough proprietary technology delivers effective, non-invasive and pain free skin care.
Jenex received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites, (including bees, wasps, hornets, mosquitoes, black flies and jellyfish). Jenex received approval for the above claims from FDA (United States) in 1997.
For further information please contact:
The Jenex Corporation
FORWARD LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events or the Company's future performance and include the proposed continuation to the laws of British Columbia and the proposed name change, as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to a number of factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release on the Investorideas.com newswire https://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.